On Tuesday, Seres Therapeutics Inc (NASDAQ: MCRB) was -3.02% drop from the session before settling in for the closing price of $0.83. A 52-week range for MCRB has been $0.54 – $1.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 477.44% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 86.52%. With a float of $124.81 million, this company’s outstanding shares have now reached $170.20 million.
In an organization with 233 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -10887.5%, operating margin of -221404.69%, and the pretax margin is -258259.37%.
Seres Therapeutics Inc (MCRB) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Seres Therapeutics Inc stocks. The insider ownership of Seres Therapeutics Inc is 26.90%, while institutional ownership is 23.87%. The most recent insider transaction that took place on Nov 18 ’24, was worth 475. In this transaction Chief Legal Officer and EVP of this company sold 878 shares at a rate of $0.54, taking the stock ownership to the 135,192 shares. Before that another transaction happened on Nov 18 ’24, when Company’s insider sold 977 for $0.54, making the entire transaction worth $528. This insider now owns 32,415 shares in total.
Seres Therapeutics Inc (MCRB) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 86.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.41% during the next five years compared to 18.22% growth over the previous five years of trading.
Seres Therapeutics Inc (NASDAQ: MCRB) Trading Performance Indicators
You can see what Seres Therapeutics Inc (MCRB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2292.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.19, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Seres Therapeutics Inc (MCRB)
Let’s dig in a bit further. During the last 5-days, its volume was 0.88 million. That was inferior than the volume of 2.12 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 34.70%. Additionally, its Average True Range was 0.07.
During the past 100 days, Seres Therapeutics Inc’s (MCRB) raw stochastic average was set at 39.59%, which indicates a significant increase from 39.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 108.31% in the past 14 days, which was higher than the 97.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8561, while its 200-day Moving Average is $0.8931. However, in the short run, Seres Therapeutics Inc’s stock first resistance to watch stands at $0.8301. Second resistance stands at $0.8546. The third major resistance level sits at $0.8693. If the price goes on to break the first support level at $0.7909, it is likely to go to the next support level at $0.7762. The third support level lies at $0.7517 if the price breaches the second support level.
Seres Therapeutics Inc (NASDAQ: MCRB) Key Stats
There are 170,738K outstanding shares of the company, which has a market capitalization of 137.55 million. As of now, sales total 126,330 K while income totals -113,720 K. Its latest quarter income was 0 K while its last quarter net income were 88,780 K.
